Company profile for Athersys

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Athersys is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our focus is on the treatment of medical conditions where there is significant clinical need, and we are particularly focused on developing therapies in the regenerative medicine area. We are developing MultiStem®, a patented, adult-derived "off-the-shelf" stem c...
Athersys is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our focus is on the treatment of medical conditions where there is significant clinical need, and we are particularly focused on developing therapies in the regenerative medicine area. We are developing MultiStem®, a patented, adult-derived "off-the-shelf" stem cell therapy platform, for disease indications in areas of neurological, inflammatory & immune, and cardiovascular disease areas, as well as other critical care indications where there is substantial unmet medical need du

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
CONTACT Athersys, Inc. 3201 Carnegie Avenue Cleveland, OH 44115
Telephone
Telephone
216-431-9900
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://endpts.com/athersys-files-for-chapter-11-bankruptcy-sells-everything-to-partner-healios/

Ayisha Sharma ENDPTS
09 Jan 2024
Athersys files for bankruptcy, sells assets to Healios
Athersys files for bankruptcy, sells assets to Healios

09 Jan 2024

// James Waldron FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/athersys-files-bankruptcy-sells-assets-healios-wake-roke-cell-therapys-struggles

James Waldron FIERCE BIOTECH
09 Jan 2024

https://www.businesswire.com/news/home/20231115819414/en

BUSINESSWIRE
16 Nov 2023

https://www.businesswire.com/news/home/20231016359283/en

BUSINESSWIRE
16 Oct 2023

https://www.businesswire.com/news/home/20231010500674/en

BUSINESSWIRE
10 Oct 2023
Athersys nears bankruptcy as cell therapy fails interim analysis
Athersys nears bankruptcy as cell therapy fails interim analysis

10 Oct 2023

// Annalee Armstrong FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/athersys-inches-closer-bankruptcy-stroke-cell-therapy-fails-interim-analysis

Annalee Armstrong FIERCE BIOTECH
10 Oct 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty